Dr S. Shahzad Mustafa highlights new systemic therapies for urticaria, their impact on quality of life, and the need for ways ...

Omalizumab 300 mg demonstrated statistically superior efficacy versus dupilumab and remibrutinib using matched-adjusted ...

Discover a study showing barzolvolimab rapidly improves chronic spontaneous urticaria symptoms, offering hope for patients ...

But in findings presented at the American College of Allergy, Asthma and Immunology (ACAAI) meeting in Orlando, the novel ...

If you notice red, itchy welts suddenly popping up on your skin, you may start to panic. Are you having an allergic reaction? Did you catch something contagious? But your mystery rash may have a much ...

Detailed price information for Celldex Therapeutics (CLDX-Q) from The Globe and Mail including charting and trades.

Washington, DC, Oct. 01, 2025 (GLOBE NEWSWIRE) -- On this Urticaria Day (UDAY), the Asthma and Allergy Foundation of America (AAFA), We CU, and The Mast Cell Disease Society (TMS) aim to raise ...

A panel of experts discuss the clinical trials of dupilumab, the resultant data, and the response of the FDA when approval was requested. Dupilumab has been evaluated in phase 3 clinical trials in ...

Pressure urticaria is a type of chronic urticaria that causes recurring hives from pressure applied to your skin. It may be treated with a combination of trigger avoidance and medications. Better ...

The reality of living with chronic hives -- which by definition last for 6 weeks or longer and have no apparent specific trigger -- can be very challenging. About half of people with "chronic ...

September 29, 2006 —The US Food and Drug Administration (FDA) has approved first-time generic formulations for caffeine citrate 10-mg/mL intravenous injection and 10-mg/mL oral solution for the ...